The Quiet Migraine Combination: Magnesium, Riboflavin, and the Mitochondrial Theory of Headache

Key Takeaways:

• The American Academy of Neurology and American Headache Society guideline on complementary treatments rates magnesium and riboflavin as Level B, “probably effective,” for preventing episodic migraine in adults.
• In a placebo-controlled trial, 600 mg of magnesium (as trimagnesium dicitrate) daily cut attack frequency by 41.6 percent by weeks 9 to 12, versus 15.8 percent on placebo; diarrhea was the main side effect.
• In a randomized trial of 400 mg riboflavin daily for three months, 59 percent of patients halved their headache days, compared with 15 percent on placebo, a number needed to treat of 2.3.

One of the most underused tools in migraine prevention sits in the supplement aisle, not the pharmacy. Prevention is worth taking seriously, because every attack avoided is a day of work, family, and sleep given back, yet many people with frequent migraine never try a preventive at all, often because they would rather not take a daily prescription drug. The joint American Academy of Neurology and American Headache Society guideline on complementary treatments reviewed the controlled trials and rated magnesium and riboflavin Level B, meaning probably effective, the same tier it gave to anti-inflammatory drugs such as ibuprofen and naproxen. A Level B rating is a genuine recommendation to consider, not a guarantee, and it rests on a handful of modest randomized trials rather than the large programs behind newer migraine drugs. Still, for people who want fewer attacks without a prescription, it is one of the better-supported places to begin, and it has the advantage of being inexpensive, widely available, and well tolerated.

The mechanisms are complementary. Magnesium sits in the channel of the NMDA glutamate receptor and holds it closed at rest, and low magnesium is thought to lower the threshold for cortical spreading depression, the slow wave of neuronal depolarization behind migraine aura, as well as to alter neurotransmitter release and platelet behavior. Riboflavin, vitamin B2, is the precursor of the flavin cofactors that run the mitochondrial electron transport chain, and a shortfall in brain energy metabolism has long been proposed as one reason a migraine-prone brain tolerates stress poorly. The trials line up with those ideas. In one, 81 adults with migraine took 600 mg of magnesium daily or placebo for twelve weeks; by the final month attacks had fallen 41.6 percent with magnesium versus 15.8 percent with placebo, and migraine days and rescue-medication use fell too. In another, 55 patients took 400 mg of riboflavin or placebo for three months; 59 percent of the riboflavin group cut their headache days by at least half, against 15 percent on placebo.

What dose of magnesium and riboflavin do the trials use?

The protocols were simple. The positive magnesium trial used 600 mg a day of trimagnesium dicitrate, a citrate salt, and the riboflavin trial used 400 mg a day, each taken for three months. That timeline is the most important practical detail, because improvement builds slowly; in the magnesium trial the benefit was measured in weeks nine through twelve, so stopping after three weeks is not a fair test. Side effects are usually minor. Diarrhea affected about one in five people on high-dose magnesium, which is often managed by splitting the dose or changing the salt, and riboflavin harmlessly turns urine bright yellow. The honest limits deserve equal weight: these trials were small, a fixed combination of magnesium, riboflavin, and coenzyme Q10 eased pain intensity but did not significantly reduce migraine days versus placebo, and people with kidney disease should not take high-dose magnesium without medical guidance. Keeping a headache diary before and during the trial makes it clear whether the combination is actually working. For many people with episodic migraine, it is one of the highest-yield, lowest-risk experiments available.

References:

1. Holland, S., Silberstein, S. D., Freitag, F., Dodick, D. W., Argoff, C., & Ashman, E. (2012). Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology, 78(17), 1346-1353.
2. Peikert, A., Wilimzig, C., & Köhne-Volland, R. (1996). Prophylaxis of migraine with oral magnesium: Results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia, 16(4), 257-263.
3. Schoenen, J., Jacquy, J., & Lenaerts, M. (1998). Effectiveness of high-dose riboflavin in migraine prophylaxis: A randomized controlled trial. Neurology, 50(2), 466-470.
4. Sun-Edelstein, C., & Mauskop, A. (2009). Role of magnesium in the pathogenesis and treatment of migraine. Expert Review of Neurotherapeutics, 9(3), 369-379.
5. Gaul, C., Diener, H. C., & Danesch, U. (2015). Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: A randomized, placebo-controlled, double-blind, multicenter trial. The Journal of Headache and Pain, 16, 516.